1 / 17

Robert H. Wiltrout Director, CCR

Director’s Address. Robert H. Wiltrout Director, CCR. Center for Cancer Research. Director Robert H. Wiltrout. Scientific Director for Basic Science Robert H. Wiltrout. Scientific Director for Clinical Science Lee Helman. Associate Director for Science L. Michelle Bennett.

kaloni
Download Presentation

Robert H. Wiltrout Director, CCR

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Director’s Address Robert H. Wiltrout Director, CCR

  2. Center for Cancer Research Director Robert H. Wiltrout Scientific Director for Basic Science Robert H. Wiltrout Scientific Director for Clinical Science Lee Helman Associate Director for Science L. Michelle Bennett Deputy Directors Douglas Lowy Jeff Strathern Larry Samelson Deputy Director Mark Udey 38 Basic Science Laboratories and Branches 15 Clinical Branches Clinical Infrastructure

  3. CCR Budget Relative to the NCI Budget CCR In 1995 the CCR budget was approximately 10% of the NCI budget In 2005 the CCR budget was approximately 7.7% of the NCI budget

  4. Percent growth 2002-2006 CCR Budget Relative to the NCI Budget CCR In 1995 the CCR budget was approximately 10% of the NCI budget In 2005 the CCR budget was approximately 7.7% of the NCI budget

  5. Mission of the Center for Cancer Research, NCI Eliminate Death and Suffering from Cancer by: - Integrating basic discovery with cutting edge technologies to create novel approaches for prevention and treatment of cancer • Providing leadership and innovation in clinical trial development and performance • Providing a distinctive venue for training the next generation of interdisciplinary basic and clinical researchers • Establishing innovative partnerships with extramural organizations and private enterprise to accelerate the translation of new discoveries and technologies to clinical application.

  6. Unique Identity of the NCI’s IRP • Distinctive critical mass and unique programmatic integration of basic, clinical and epidemiologic scientists within a unified environment • Review and reward structure that allows long-term, high-risk basic and clinical research • Allows and encourages rapid changes in direction and response to new opportunities and national priorities • Ability to fuse basic science with the newest technologies for novel clinical trials within the state of the art Clinical Research Center • Ability to recruit diverse cohorts of patients to perform science-driven, concept-based clinical trials • Distinctive and highly acclaimed interdisciplinary training programs for the next generation of biomedical scientists • Mandate and freedom to collaborate widely and provide leadership for new basic and clinical research paradigms • Higher stringency for avoidance of conflicts of interest than many other research institutions

  7. Distinctive Qualities of CCR • Critical mass of basic and clinical scientists solving complex scientific problems • Can quickly redeploy resources to address: (a) NCI mission goals (b) Urgent public need (c) New opportunities • Access to NIH Clinical Center

  8. Cancer Biology and Etiology Clinical Infrastructure and Support Molecular Targets and Molecular Oncology Immunology, Immunotherapy, and Immunoprophylaxis Genetics and Genomics HIV/AIDS Research Imaging and Biomarkers Advanced Biomedical Technologies CCR Infrastructure Discovery Research Translational Research Training Clinical Research HIV/AIDS Research The Center for Cancer Research:A Comprehensive Translational Research Program

  9. CCR Major Theme Areas

  10. Infrastructure to Support Translational Multidisciplinary Research

  11. Centers of Excellence: Focal Points for Bench to Bedside Translation These Centers of Excellence serve to support the IRPs dedication to long-term, high-risk, innovative basic, clinical, and epidemiologic research. Immunology Chromosome Biology Advanced Biomedical Technology Molecular Epidemiology Molecular Oncology

  12. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * + * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * - Clinical Research - Basic Research How Reengineering is Reshaping Interactions in the CCR + + + + + + + + + + + + + + + + + + * + + Reengineering and Redeployment * + + * + * + * * + + * * + * + * + + + + * * + + * Before After + - Other NCI entities - Outside of NCI

  13. Warren Grant Magnuson Clinical Center Mark O. Hatfield Clinical Research Center NIH Clinical Center

  14. The NCI Intramural Clinical Research Program • The NCI intramural clinical program is not a large volume, full-service cancer center • The NCI intramural clinical program is the largest cancer-focused clinical research center (CRC) in the world, capable of performing patient-intensive clinical research focused on developing new approaches for prevention, diagnosis, and treatment of cancer. • The NCI intramural clinical program is an important component of the nation’s overall cancer program

  15. Clinical Molecular Profiling Core All CCR Clinical Protocols Biospecimen Procurement and Processing Facility LCM, Annotation Clinical Molecular Profiling Core Genomic Analysis -Array CGH - Kinome resequencing -SNP analysis - etc Tissue Array IHC Etc Expression Profiling Tissue Proteomics Development

  16. Vision for the Future • Focus on testing new science-based hypotheses interrogating a disease or disease process • Maximize our understanding of how to intervene in the disease process by interrogating the cancer network using genetic, proteomic, and imaging tools

More Related